CRISPR gene editing for sickle cell disease: one disease, differentiated approaches

Cell & Gene Therapy Insights 2021; 7(7), 851–856

10.18609/cgti.2021.116

Published: 5 August 2021
Editorial
Lisa A Michaels, MD, Bruce E Eaton, PhD

Lisa A Michaels, MD

Chief Medical Officer, Editas Medicine

Bruce E Eaton, PhD

Chief Business Officer, Editas Medicine